Journal Mobile Options
Table of Contents
Vol. 38, No. 1, 2003
Issue release date: January 2003
Pediatr Neurosurg 2003;38:27–33

The Effect of Intrauterine Myelomeningocele Repair on the Incidence of Shunt-Dependent Hydrocephalus

Tulipan N. · Sutton L.N. · Bruner J.P. · Cohen B.M. · Johnson M. · Adzick N.S.
Departments of aNeurosurgery and bObstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tenn., cDepartment of Surgery, dDivision of Biostatistics and Epidemiology, eThe Center for Fetal Diagnosis and Treatment, The Children’s Hospital of Philadelphia, The University of Pennsylvania Medical School, Philadelphia, Pa., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Intrauterine myelomeningocele repair (IUMR) was first successfully performed in 1997. Preliminary reports suggest that this procedure reduces the incidence of shunt-dependent hydrocephalus when compared to conventional postnatal therapy. However, the existing cohort of IUMR patients has not yet been systematically compared to a comparable group of conventionally treated controls. Methods: Patients 1 year old or greater who had undergone IUMR at either Vanderbilt University or the Children’s Hospital of Philadelphia (CHOP) were compared to a group of conventionally treated historical controls treated and followed at CHOP. In order to measure any differences between the groups, patients were stratified according to the level of the myelomeningocele lesion and the gestational age at the time of IUMR. Results: One hundred and four IUMR patients were compared to 189 conventionally treated controls. IUMR resulted in statistically significant reductions in the incidence of shunt-dependent hydrocephalus at both lumbar and sacral lesion levels. When lumbar lesion levels were further stratified, from L1 to L5, it appeared that the benefit of IUMR was statistically significant only at levels below L2. Other factors with a significant impact on hydrocephalus were estimated gestational age and ventricular size at the time of surgery. In particular, statistically significant differences compared to controls were seen in the younger (≤25 weeks) group but not in the older (>25 weeks) group. Conclusions: IUMR appears to substantially reduce the incidence of shunt-dependent hydrocephalus when compared to conventional treatment even when lesion level is taken into account. Patients with lesions above L3 may not share in this benefit. IUMR cannot be justified in fetuses older than 25 weeks of gestation. Additional improvements might be obtained by further reducing the average age at which fetuses are operated upon. It remains to be determined whether this benefit outweighs the potential risks of intrauterine surgery.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Staal MJ, Meihuizen-de Regt MJ, Hess J: Sudden death in hydrocephalic spina bifida aperta patients. Pediatr Neurosci 1987;13:13–18.
  2. Iskandar BJ, Tubbs S, Mapstone TB, Grabb PA, Bartolucci AA, Oakes WJ: Death in shunted hydrocephalic children in the 1990s. Pediatr Neurosurg 1998;28:173–176.
  3. Stevenson RE, Allen WP, Pai GS, Best R, Seaver LH, Dean J, Thompson S: Decline in prevalence of neural tube defects in a high-risk region of the United States. Pediatrics 2000;106:677–683.

    External Resources

  4. Tulipan N, Bruner JP: Myelomeningocele repair in utero: A report of three cases. Pediatr Neurosurg 1998;28:177–180.
  5. Adzick NS, Sutton LN, Crombleholme TM, Flake AW: Successful fetal surgery for spina bifida. Lancet 1998;352:1675–1676.
  6. Heffez DS, Aryanpur J, Hutchins GM, Freeman JM: The paralysis associated with myelomeningocele: Clinical and experimental data implicating a preventable spinal cord injury. Neurosurgery 1990;26:987–992.
  7. Walsh DS, Adzick NS, Sutton LN, Johnson MP: The rationale for in utero repair of myelomeningocele. Fetal Diagn Ther 2001;16:312–322.
  8. Tulipan N, Henanz-Schulman M, Lowe LH, Bruner JP: Intrauterine myelomeningocele repair reverses preexisting hindbrain herniation. Pediatr Neurosurg 1999;31:137–142.
  9. Sutton LN, Adzick NS, Bilaniuk LT, Johnson MP, Crombleholme TM, Flake AW: Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imaging following fetal surgery for myelomeningocele. JAMA 1999;282:1826–1831.
  10. Bruner JP, Tulipan NB, Paschall RL, Boehm FH, Walsh WF, Silva SR, Henanz-Schulman M, Lowe LH, Reed GW: Fetal surgery for myelomeningocele and the incidence of shunt-dependent hydrocephalus. JAMA 1999;282:1819–1825.
  11. Rintoul N, Sutton LN, Hubbard AM, Cohen B, Melchionni J, Pasquariello PS, Adzick NS: A new look at myelomeningoceles: Functional level, vertebral level, shunting and the implications for fetal intervention. Pediatrics 2002;109:409–413.

    External Resources

  12. Tulipan N, Bruner JP, Hernanz-Schulman M, Lowe LH, Walsh WF, Nikolaus D, Oaks WJ: Effect of intrauterine myelomeningocele repair on central nervous system structure and function. Pediatr Neurosurg 1999;31:183–188.
  13. Bowman RM, McLone DG, Grant JA, Tomita T, Ito JA: Spina bifida outcome: A 25-year perspective. Pediatr Neurosurg 2001;34:114–120.
  14. Babcook CJ, Goldstein RB, Barth RA, Damato NM, Callen PW, Filly RA: Prevalence of ventriculomegaly in association with myelomeningocele: Correlation with gestational age and severity of posterior fossa deformity. Radiology 1994;190:703–707.
  15. McLone DG, Knepper PA: The cause of Chiari II malformation: A unified theory. Pediatr Neurosci 1989;15:1–12.
  16. Hamdan AH, Walsh W, Hedding A, Bruner JP, Tulipan N: Gestational age at intrauterine myelomeningocele repair does not influence the risk of prematurity. Fetal Diagn Ther 2002;17:66–68.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50